Actively Recruiting
Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers
Led by University of California, San Francisco · Updated on 2025-10-06
28
Participants Needed
2
Research Sites
403 weeks
Total Duration
On this page
Sponsors
U
University of California, San Francisco
Lead Sponsor
V
Varian Medical Systems
Collaborating Sponsor
AI-Summary
What this Trial Is About
This phase II trial studies how well radiation therapy works for the treatment of gastrointestinal cancer that are spreading to other places in the body (metastatic). Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. This trial is being done to determine if giving radiation therapy to patients who are being treated with immunotherapy and whose cancers are progressing (getting worse) can slow or stop the growth of their cancers. It may also help researchers determine if giving radiation therapy to one tumor can stimulate the immune system to attack other tumors in the body that are not targeted by the radiation therapy.
CONDITIONS
Official Title
Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have a confirmed metastatic gastrointestinal cancer (including esophageal, gastroesophageal, gastric, small intestine, hepatocellular, pancreaticobiliary, colorectal, or anal cancer)
- Currently receiving immunotherapy with progressive disease by RECIST criteria
- Have at least two progressing metastases, with one tumor safe to leave unirradiated as determined by a radiation oncologist
- Have 1 to 5 sites of disease suitable for palliative radiation therapy as judged by a radiation oncologist
- Evaluated by a radiation oncologist within 28 days before study registration
- Have adequate organ function to receive radiation therapy and immunotherapy
- Are 18 years or older
- Have a life expectancy of more than 6 months
- Have an ECOG performance status of 0 to 2 or Karnofsky score of 50 or higher
- Agree to use effective contraception if of child-bearing potential (women) or as a male participant, during and after radiation therapy
- If a woman of child-bearing potential, have a negative pregnancy test within 28 days before enrollment
- Able to understand and willing to sign informed consent
You will not qualify if you...
- Enrolled in an immunotherapy clinical trial that does not allow radiation therapy
- Received radiation therapy within 4 weeks before study enrollment
- Treated with systemic corticosteroids or immunosuppressive drugs that reduce immunotherapy effect
- Have a medical contraindication to radiation therapy as determined by a radiation oncologist
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
University of California, San Francisco
San Francisco, California, United States, 94143
Actively Recruiting
2
John Muir Medical Center-Walnut Creek
Walnut Creek, California, United States, 94598
Not Yet Recruiting
Research Team
L
Luchia Andemicael
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here